This article is more than 5 years old. Information may no longer be current.
Baseline signs of AMD present in most VIEW 1, VIEW 2 fellow eyes
Click Here to Manage Email Alerts
SAN DIEGO — Signs of early or late age-related macular degeneration were present in the vast majority of contralateral eyes of patients enrolled in the VIEW 1 and VIEW 2 studies, according to a poster presented at the American Society of Retina Specialists annual meeting.
Anat Loewenstein, MD, conducted a pooled post hoc analysis of medical history data for 2,412 VIEW 1 and VIEW 2 study participants, examining baseline best corrected visual acuity, drusen presence, pigment presence, evidence of choroidal neovascularization and lens status.
“Patients’ perception of their visual function relies primarily on the visual acuity in the better-seeing eye,” Loewenstein wrote in the poster.
At baseline, the fellow eye was the better-seeing eye in 76.2% of patients.
Mean baseline BCVA in study eyes was 53.8 letters, compared with 65.2 letters in fellow eyes.
No significant difference was seen in terms of lens status at baseline for study and contralateral eyes, according to Loewenstein.
Signs of AMD were found in the majority of fellow eyes at baseline, with evidence of prior CNV found in 34.6% of these eyes.
“Additional studies are needed to evaluate the development of new CNV in the fellow eye and whether prompt treatment of these relatively early CNV lesions results in better outcomes,” Lowenstein wrote.
Disclosure: Lowenstein is a consultant for Alimera Sciences, Alcon, Allergan, Bayer, ForSight Labs, Lumenis, Notal Vision, Novartis, Ora Bio and Teva Pharmaceutical Industries.